Scholar Rock Q3 revenue widens to $107.2 million
By Liezl GambeKey points
- Scholar Rock (NASDAQ:SRRK) reported third-quarter 2026 revenue of US$570,000 from initial ISEMBYLD shipments, below analyst expectations of US$1.43 million.
- The company reported a net loss of US$107.2 million, or US$0.81 per share, beating the analyst loss estimate of US$0.84 per share.
- Scholar Rock began the US launch of ISEMBYLD following FDA approval and agreed to sell its Priority Review Voucher for US$205 million.
Scholar Rock (NASDAQ:SRRK) reported third-quarter 2026 revenue of US$570,000 from initial shipments of ISEMBYLD, missing analyst estimates of US$1.43 million despite reporting a smaller-than-expected loss per share.
Revenue came entirely from initial product shipments, while the company's net loss increased to US$107.2 million from US$102.2 million in the prior-year quarter, although its US$0.81 loss per share beat the US$0.84 analyst estimate.
Research and development expenses increased to US$54.1 million from US$50.5 million, while selling, general and administrative expenses reached US$52.5 million compared with US$53.1 million a year earlier, and quarter-end cash, cash equivalents and marketable securities totaled US$413.6 million.
Following the announcement, Scholar Rock shares fell 3.03% in premarket trading to US$49.99, compared with the previous closing price of US$51.55.
The company received FDA approval for ISEMBYLD (apitegromab-mstn) on September 11, 2026, making it the first muscle-targeted therapy approved for children and adults aged two years and older living with spinal muscular atrophy who receive SMN2-targeted treatment.
Scholar Rock is also pursuing international regulatory approvals, with its European application resubmitted and its Japanese application accepted for priority review, while its US$205 million Priority Review Voucher sale remains subject to closing conditions.
